INFO & CONTACTS:  +39 02 2390 1

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)

Phase: Phase III clinical trials

Principal Investigator: Dott. Lo Russo Giuseppe

Main Facility: Oncologia Medica Toraco-Polmonare

Drug: V940

Pathologies: Lung cancer

Eligible participants will receive neoadjuvant pembrolizumab with chemotherapy after which they will undergo potentially curative surgery.

Patients who are found to be eligible for randomization following surgery will be divided into two arms:

Arm A: Pembrolizumab will be administered in combination with V940

Arm B: Pebrolizumab will be administered in combination with placevo (control arm)

The main purpose of the study is to evaluate the safety and efficacy of V940 in combination with Pembrolizumab

Last update: 14/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe